- Title
- 2542eTiP Phase I/II dose escalation and expansion of AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC): The ARTISAN trial
- Creators
- O. Sartor - Tulane UniversityJ.S. de Bono - Royal Marsden HospitalC. Artigas - Institut Jules BordetP. Flamen - Institut Jules BordetE. Verburg - Erasmus MCL.T. Nordquist - Urology Cancer Center and GU Research NetworkM.J. Morris - Memorial Sloan Kettering Cancer CenterM.N. Stein - Columbia UniversityV. Jardine - Tama Art UniversityL. Bouzelmat - Artistic Realization TechnologiesV. Paulus - Cambridge SchoolM. Suppiah-Coll - Artistic Realization TechnologiesR. Greasley - Royal College of ArtJ. Needham-Clark - Artistic Realization TechnologiesT. Aarvak - Oslo National Academy of the ArtsI. Galetic - Department of Biomedicine BaselM. Yu - Clinical Development, ARTBIO Inc., Cambridge, United States of AmericaR. Wahl - Washington University in St. Louis
- Publication Details
- Annals of oncology, Vol.36, pp.S1283-S1284
- Publisher
- Elsevier Ltd
- Identifiers
- 991006262538802656
- Academic Unit
- Radiology
- Language
- English
- Resource Type
- Journal article
Journal article
2542eTiP Phase I/II dose escalation and expansion of AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC): The ARTISAN trial
Annals of oncology, Vol.36, pp.S1283-S1284
09/2025
Metrics
1 Record Views